• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

新冠后状况下的血管纤维化与细胞外基质重塑

Vascular fibrosis and extracellular matrix remodelling in post-COVID 19 conditions.

作者信息

Kamdar Anna, Sykes Robert, Thomson Cameron R, Mangion Kenneth, Ang Daniel, Lee Michelle Aw, Van Agtmael Tom, Berry Colin

机构信息

School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow G12 8TA, UK.

West of Scotland Heart and Lung Centre, Golden Jubilee National Hospital, Glasgow G81 4DY, UK.

出版信息

Infect Med (Beijing). 2024 Oct 19;3(4):100147. doi: 10.1016/j.imj.2024.100147. eCollection 2024 Dec.

DOI:10.1016/j.imj.2024.100147
PMID:39649442
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11621938/
Abstract

Causal associations between viral infections and acute myocardial injury are not fully understood, with mechanisms potentially involving direct cardiovascular involvement or systemic inflammation. This review explores plausible mechanisms of vascular fibrosis in patients with post-COVID-19 syndrome, focusing on extracellular matrix remodelling. Despite global attention, significant mechanistic or translational breakthroughs in the management of post-viral syndromes remain limited. No effective pharmacological or non-pharmacological interventions are currently available for patients experiencing persistent symptoms following COVID-19 infection. The substantial expansion of scientific knowledge resulting from collaborative efforts by medical experts, scientists, and government organisations in undertaking COVID-19 research could inform treatment strategies for other post-viral syndromes and respiratory illnesses. There is a critical need for clinical trials to evaluate potential therapeutic candidates, providing evidence to guide treatment decisions for post-COVID-19 syndromes.

摘要

病毒感染与急性心肌损伤之间的因果关联尚未完全明确,其机制可能涉及直接的心血管受累或全身炎症。本综述探讨了新冠后综合征患者血管纤维化的可能机制,重点关注细胞外基质重塑。尽管受到全球关注,但病毒感染后综合征管理方面的重大机制或转化突破仍然有限。目前,对于新冠感染后仍有持续症状的患者,尚无有效的药物或非药物干预措施。医学专家、科学家和政府组织在开展新冠研究方面的合作努力所带来的科学知识大幅扩展,可为其他病毒感染后综合征和呼吸道疾病的治疗策略提供参考。迫切需要进行临床试验以评估潜在的治疗候选药物,为指导新冠后综合征的治疗决策提供证据。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2570/11621938/8df07b6381ad/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2570/11621938/a09fd1239178/ga1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2570/11621938/44d7c7633954/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2570/11621938/8df07b6381ad/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2570/11621938/a09fd1239178/ga1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2570/11621938/44d7c7633954/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2570/11621938/8df07b6381ad/gr2.jpg

相似文献

1
Vascular fibrosis and extracellular matrix remodelling in post-COVID 19 conditions.新冠后状况下的血管纤维化与细胞外基质重塑
Infect Med (Beijing). 2024 Oct 19;3(4):100147. doi: 10.1016/j.imj.2024.100147. eCollection 2024 Dec.
2
Providing Access To Monoclonal Antibody Treatment Of Coronavirus (COVID-19) Patients In Rural And Underserved Areas (Archived)为农村及服务欠缺地区的冠状病毒病(COVID-19)患者提供单克隆抗体治疗(存档)
3
Cardiovascular disease and COVID-19: a consensus paper from the ESC Working Group on Coronary Pathophysiology & Microcirculation, ESC Working Group on Thrombosis and the Association for Acute CardioVascular Care (ACVC), in collaboration with the European Heart Rhythm Association (EHRA).心血管疾病与 COVID-19:ESC 冠状动脉病理生理学和微循环工作组、ESC 血栓形成工作组以及急性心血管护理协会(ACVC)与欧洲心律协会(EHRA)合作的共识文件。
Cardiovasc Res. 2021 Dec 17;117(14):2705-2729. doi: 10.1093/cvr/cvab298.
4
Multidisciplinary collaborative guidance on the assessment and treatment of patients with Long COVID: A compendium statement.关于长新冠患者评估与治疗的多学科协作指南:一份概要声明
PM R. 2025 Apr 22. doi: 10.1002/pmrj.13397.
5
Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.在流行地区,服用抗叶酸抗疟药物的人群中,叶酸补充剂与疟疾易感性和严重程度的关系。
Cochrane Database Syst Rev. 2022 Feb 1;2(2022):CD014217. doi: 10.1002/14651858.CD014217.
6
Non-Pharmacological Therapies for Post-Viral Syndromes, Including Long COVID: A Systematic Review.病毒性疾病后综合征(包括长新冠)的非药物治疗:系统评价。
Int J Environ Res Public Health. 2023 Feb 16;20(4):3477. doi: 10.3390/ijerph20043477.
7
Monoclonal Antibody Therapy For High-Risk Coronavirus (COVID 19) Patients With Mild To Moderate Disease Presentations (Archived)针对轻度至中度症状的高危冠状病毒(COVID-19)患者的单克隆抗体疗法(存档)
8
Pathogenic mechanisms of post-acute sequelae of SARS-CoV-2 infection (PASC).SARS-CoV-2 感染后后遗症(PASC)的发病机制。
Elife. 2023 Mar 22;12:e86002. doi: 10.7554/eLife.86002.
9
Animal models of post-acute COVID-19 syndrome: a call for longitudinal animal studies.急性 COVID-19 综合征后动物模型:呼吁开展纵向动物研究。
Front Immunol. 2025 Feb 26;16:1521029. doi: 10.3389/fimmu.2025.1521029. eCollection 2025.
10
Post-COVID pulmonary sequelae: Mechanisms and potential targets to reduce persistent fibrosis.新冠后肺部后遗症:减少持续性纤维化的机制及潜在靶点
Pharmacol Ther. 2025 Aug;272:108891. doi: 10.1016/j.pharmthera.2025.108891. Epub 2025 May 28.

引用本文的文献

1
APNet, an explainable sparse deep learning model to discover differentially active drivers of severe COVID-19.APNet,一种可解释的稀疏深度学习模型,用于发现重症新冠肺炎的差异活跃驱动因素。
Bioinformatics. 2025 Mar 4;41(3). doi: 10.1093/bioinformatics/btaf063.

本文引用的文献

1
Myocardial Ischemia of Nonobstructive Origin as a Cause of New-Onset Chest Pain in Long-COVID Syndrome.非阻塞性原因引起的心肌缺血作为长新冠综合征新发胸痛的一个病因
JACC Cardiovasc Interv. 2024 Apr 8;17(7):958-960. doi: 10.1016/j.jcin.2024.01.072.
2
Cardiac MRI Findings in Patients Clinically Referred for Evaluation of Post-Acute Sequelae of SARS-CoV-2 Infection.因新型冠状病毒肺炎急性后遗症评估而临床转诊患者的心脏磁共振成像结果
Diagnostics (Basel). 2023 Jun 26;13(13):2172. doi: 10.3390/diagnostics13132172.
3
Vascular mechanisms of post-COVID-19 conditions: Rho-kinase is a novel target for therapy.
新冠病毒感染后病症的血管机制:Rho 激酶是一种新的治疗靶点。
Eur Heart J Cardiovasc Pharmacother. 2023 Jun 2;9(4):371-386. doi: 10.1093/ehjcvp/pvad025.
4
Cardiac magnetic resonance -detected myocardial injury is not associated with long-term symptoms in patients hospitalized due to COVID-19.心脏磁共振检测到的心肌损伤与因 COVID-19 住院的患者的长期症状无关。
PLoS One. 2023 Mar 8;18(3):e0282394. doi: 10.1371/journal.pone.0282394. eCollection 2023.
5
Myocardial Involvement After Hospitalization for COVID-19 Complicated by Troponin Elevation: A Prospective, Multicenter, Observational Study.因 COVID-19 住院且肌钙蛋白升高并发心肌损伤:一项前瞻性、多中心、观察性研究。
Circulation. 2023 Jan 31;147(5):364-374. doi: 10.1161/CIRCULATIONAHA.122.060632. Epub 2023 Jan 27.
6
Acute and postacute sequelae associated with SARS-CoV-2 reinfection.与 SARS-CoV-2 再感染相关的急性和后期后遗症。
Nat Med. 2022 Nov;28(11):2398-2405. doi: 10.1038/s41591-022-02051-3. Epub 2022 Nov 10.
7
Elevated vascular transformation blood biomarkers in Long-COVID indicate angiogenesis as a key pathophysiological mechanism.长期 COVID 患者血管转化血液生物标志物升高表明血管生成是关键的病理生理机制。
Mol Med. 2022 Oct 10;28(1):122. doi: 10.1186/s10020-022-00548-8.
8
The fatal trajectory of pulmonary COVID-19 is driven by lobular ischemia and fibrotic remodelling.肺 COVID-19 的致命轨迹是由小叶性缺血和纤维性重塑驱动的。
EBioMedicine. 2022 Nov;85:104296. doi: 10.1016/j.ebiom.2022.104296. Epub 2022 Oct 4.
9
Cytokine Profiles Associated With Acute COVID-19 and Long COVID-19 Syndrome.与急性 COVID-19 和长新冠综合征相关的细胞因子谱。
Front Cell Infect Microbiol. 2022 Jun 30;12:922422. doi: 10.3389/fcimb.2022.922422. eCollection 2022.
10
Long COVID burden and risk factors in 10 UK longitudinal studies and electronic health records.10 项英国纵向研究和电子健康记录中的长新冠负担和风险因素。
Nat Commun. 2022 Jun 28;13(1):3528. doi: 10.1038/s41467-022-30836-0.